BioSpace News Archive

LIXTE Biotechnology Holdings, Inc. announced the appointment of Jan Schellens, M.D., Ph.D., as Chief Medical Officer.

AbbVie (NYSE: ABBV) will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024.

TuHURA Biosciences, Inc. and Kintara Therapeutics, Inc. announced positive results from the primary analysis of TuHURA’s completed Phase 1b trial evaluating IFx-2.0 among patients with advanced or metastatic MCC or cSCC who exhibited primary resistance to immune checkpoint inhibitor therapy.

Monogram Technologies Inc., an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, will host an investor and analyst day on Thursday, June 20th, 2024, from 9:00 a.m. CDT to 1:00 p.m. CDT at its cadaver lab and headquarters in Austin, Texas.

BioPharmaSpec, the leading global Contract Research Organization for discovery and preclinical characterization of biopharmaceuticals, has made major new investments in instrumentation, including top-of-the-range Mass Spectrometers, to support its clients in their product development goals.

Merck KGaA, Darmstadt, Germany, a leading science and technology company that operates its Healthcare business as EMD Serono in the US and Canada, today shared updates on the company’s oncology pipeline and focused approach to the research and development of potential new medicines designed to improve the futures of people with cancer.

AIM ImmunoTech Inc., announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM will participate in the Virtual Investor Lunch Break Series on Wednesday, June 5, 2024 at 12:00 PM ET.

Guardant Health, Inc. (Nasdaq: GH) announced its research collaborators from Washington University’s Siteman Cancer Center will lead an oral presentation today at the 2024 American Society for Clinical Oncology (ASCO) Annual Meeting highlighting the potential role of liquid biopsy in addressing racial inequities in enrollment in clinical trials and in the use of targeted therapies for advanced breast cancer.

Ori Biotech Ltd. (Ori), a leader in cell and gene therapy (CGT) manufacturing technology, and CTMC - a joint venture between Resilience + MD Anderson Cancer Center, announces promising results for IRO, Ori’s newly launched next-generation CGT manufacturing enabling platform.

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today released positive Phase 1/2 pivotal study results for the investigational PRGN-2012 off-the-shelf (OTS) AdenoVerse® gene therapy in patients with recurrent respiratory papillomatosis (RRP).